A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants
A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects
研究概览
详细说明
The drug being tested in this study is called TAK-954. This study will assess the mass balance, metabolic profiles and routes of elimination of single intravenous dose of [14C]-TAK-954, and will determine the major circulating and excreted metabolites and single-dose PK of total radioactivity, TAK-954, THRX513466, and THRX 913682 in healthy male participants.
The study will enroll approximately 6 participants. All participants will receive a single dose of [14C]-TAK-954 0.5 mg on Day 1.
This single-center trial will be conducted in Netherlands. The overall time to participate in this study is approximately 6 to 7 weeks. Participants will make a final visit to the clinic 15 days after last dose of study drug for a follow-up assessment.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Groningen、荷兰、9728 NZ
- PRAHS
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Be a man aged 18 to 55 years, inclusive, at the screening visit.
- Have a body mass index (BMI) greater than or equal to (>=) 18 and less than or equal to (<=) 30 kilogram per square meter (kg/m^2) and a body weight greater than (>) 50 kilogram (kg) at the screening visit.
- Be a nonsmoker who has not used tobacco- or nicotine-containing products (example, nicotine patch) for at least 6 months before administration of the initial dose of trial drug.
Meet the following birth control requirements:
- Is a male participant who is sterile or agrees to use an appropriate method of contraception, including a condom, from the first dose of study drug until 30 days after the last dose of study drug. No restrictions are required for a vasectomized male participant provided that the participant is at least 1 year postbilateral vasectomy procedure before the first dose of study drug. A male participant whose vasectomy procedure was performed less than 1 year before the first dose of study drug must follow the same restrictions as a nonvasectomized man. Appropriate documentation of surgical procedures should be provided.
- Is a male participant who agrees to not donate sperm from trial drug administration on the first day of the first dose until 30 days after the last dose of study drug.
Exclusion Criteria:
- Has total 14C radioactivity measured by accelerator mass spectrometry in plasma (during screening) exceeding 14C/12C ratio 1.1E-12.
- Participated in any study with a radiation dose above 0.1 millibecquerel (MBq) or radiation burden above 0.1 millisievert (mSv) within 1 year before screening.
- Was exposed to significant radiation (example, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months before check-in.
- Irregular defecation pattern (less than once per 2 days).
- Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to beer 354 milliliter [mL]/12 ounce [oz], wine 118 mL/4 oz, or distilled spirits 29.5 mL/1 oz).
- Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
- Has a substance abuse disorder.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:[14C]-TAK-954 0.5 mg
[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
|
[14C]-TAK-954 intravenous infusion.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Cumulative Percentage of Administered Radioactivity Recovered in Urine
大体时间:Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
|
Cumulative Percentage of Administered Radioactivity Recovered in Feces
大体时间:Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
|
Cumulative Percentage of Radioactivity in Urine and Feces Combined
大体时间:Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
|
Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine and Feces Combined
大体时间:Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Percentage of dose recovered for TAK-954 and its metabolites derived from 0-168 hour sampling was normalized for 100% recovery.
|
Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine
大体时间:Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Percentage of dose recovered for TAK-954 and its metabolites derived from 0-168 hour sampling was normalized for 100% recovery.
|
Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Feces
大体时间:Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Percentage of dose recovered for TAK-954 and its metabolites derived from 0-168 hour sampling was normalized for 100% recovery.
|
Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Mean Percent of Total Radioactivity in Plasma for TAK-954 and TAK-954 Metabolites
大体时间:Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
|
Cumulative Percentage of Dose Excreted in Urine for TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose
|
|
Cumulative Percentage of Dose Excreted in Feces for TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
The cumulative percentage of dose excreted in feces as TAK-954 derived from 0-168 hour sampling was normalized for 100% recovery.
|
Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Mean Concentration of Total Radioactivity in Whole Blood and Plasma [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Cmax: Maximum Observed Plasma and Whole Blood Concentrations of Radioactivity for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Cmax: Maximum Observed Plasma Concentration for TAK-954 and TAK-954 Metabolites
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 and TAK-954 Metabolites
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
AUC∞: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to Infinity for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 and TAK-954 Metabolites
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-954 and TAK-954 Metabolites
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
t1/2z: Terminal Disposition Phase Half-life of Radioactivity in Plasma and Whole Blood for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
t1/2z: Terminal Disposition Phase Half-life in Plasma for TAK-954 and TAK-954 Metabolites
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
CL: Total Clearance After Intravenous Administration for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
CL: Total Clearance of TAK-954 After Intravenous Administration of [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Aet Urine: Amount of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Aet Urine: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Aet Feces: Amount of Total Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Fet Urine: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Fet Urine: Fraction of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
|
Fet Feces: Fraction of Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Ratio of Total Radioactivity in Whole Blood to Plasma
大体时间:Day 1 pre-dose and at multiple time points (up to 264 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 264 hours) post-dose
|
Ratio of AUC∞: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 to Total Radioactivity in Plasma TAK-954
大体时间:Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
|
Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)
大体时间:Baseline up to Day 31
|
Baseline up to Day 31
|
Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of [14C]-TAK-954
大体时间:Baseline up to Day 15
|
Baseline up to Day 15
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- TAK-954-1005
- U1111-1202-5762 (其他标识符:WHO)
- NL65503.056.18 (注册表标识符:NL)
- 2018-001181-42 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
[14C]-TAK-954的临床试验
-
Millennium Pharmaceuticals, Inc.完全的
-
Neurocrine BiosciencesTakeda完全的
-
Millennium Pharmaceuticals, Inc.完全的
-
Calithera Biosciences, Inc撤销晚期实体肿瘤 | Lymphoma Neoplasms